Frequencies and mechanisms of resistance to moxifloxacin in nosocomial isolates of Acinetobacter baumannii

Journal of Antimicrobial Chemotherapy

Volumn 52, Issue 4, 2003, Pages 687-690

  Spence, Richard P ^a   Towner, Kevin J ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Acinetobacter; Fluoroquinolones; gyrA; parC; Resistant

Indexed keywords

CIPROFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SERINE;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIUM ISOLATE; CHROMOSOME MUTATION; CODON; CONTROLLED STUDY; CULTURE MEDIUM; DNA EXTRACTION; GENE AMPLIFICATION; HOSPITAL INFECTION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; UNITED KINGDOM;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; AZA COMPOUNDS; CROSS INFECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; QUINOLINES;

EID: 0141963046     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg424     Document Type: Article

References (10)

1. Bergogne-Berezin, E. & Towner, K. J. (1996). Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clinical Microbiology Reviews 9, 148-65.
2. Towner, K. J. (1997). Clinical importance and antibiotic resistance of Acinetobacter spp. Journal of Medical Microbiology 46, 721-46.
3. Vila, J., Ruiz, J., Goni, P. et al. (1995). Mutation in the gyrA gene of quinolone-resistant clinical isolates of Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy 39, 1201-3.
4. Vila, J., Ruiz, J., Goni, P. et al. (1997). Quinolone-resistance mutations in the topoisomerase IV parC gene of Acinetobacter baumannii. Journal of Antimicrobial Chemotherapy 39, 757-62.
5. Magnet, S., Courvalin, P. & Lambert, T. (2001). Resistance-nodulation-cell division-type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain BM4454. Antimicrobial Agents and Chemotherapy 45, 3375-80.
6. Vila, J., Ribera, A., Marco, F. et al. (2002). Activity of clinafloxacin, compared with six other quinolones, against Acinetobacter baumannii clinical isolates. Journal of Antimicrobial Chemotherapy 49, 471-7.
7. Wisplinghoff, H., Decker, M., Haefs, C. et al. (2003). Mutations in gyrA and parC associated with resistance to fluoroquinolones in epidemiologically defined clinical strains of Acinetobacter baumannii. Journal of Antimicrobial Chemotherapy 51, 177-80.
8. Spence, R. P., Towner, K. J., Henwood, C. J. et al. (2002). Population structure and antibiotic resistance of Acinetobacter DNA group 2 and 13TU isolates from hospitals in the UK. Journal of Medical Microbiology 51, 1107-12.
9. Andrews, J. M. (2001). BSAC standardized disc susceptibility testing method. Journal of Antimicrobial Chemotherapy 48, Suppl. S1, 43-57.
10. MacGowan, A. P. & Wise, R. (2001). Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests. Journal of Antimicrobial Chemotherapy 48, Suppl. S1, 17-28.